CDK4/6 inhibitors in advanced breast cancer, what is beyond?
Resistant to hormonal treatment considered the main clinical challenge in the management of advanced breast cancer (ABC). The use of CDK4/6 inhibitors (CDK4/6I) may change the treatment landscape. In this mandated review, we will focus on the applicable role of CDK4/6I in the management of HR+/HER2-...
| Main Authors: | , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Frontiers Media S.A.
2019-07-01
|
| Series: | Oncology Reviews |
| Subjects: | |
| Online Access: | https://www.oncologyreviews.org/index.php/or/article/view/416 |
| _version_ | 1797963055648210944 |
|---|---|
| author | Amrallah A. Mohammed Hanaa Rashied Fifi Mostafa Elsayed |
| author_facet | Amrallah A. Mohammed Hanaa Rashied Fifi Mostafa Elsayed |
| author_sort | Amrallah A. Mohammed |
| collection | DOAJ |
| description | Resistant to hormonal treatment considered the main clinical challenge in the management of advanced breast cancer (ABC). The use of CDK4/6 inhibitors (CDK4/6I) may change the treatment landscape. In this mandated review, we will focus on the applicable role of CDK4/6I in the management of HR+/HER2- ABC, mechanisms of resistance, and promising future implementation. |
| first_indexed | 2024-04-11T01:22:21Z |
| format | Article |
| id | doaj.art-0b9201e0cdba4c36892bca9c726d1cb8 |
| institution | Directory Open Access Journal |
| issn | 1970-5557 1970-5565 |
| language | English |
| last_indexed | 2024-04-11T01:22:21Z |
| publishDate | 2019-07-01 |
| publisher | Frontiers Media S.A. |
| record_format | Article |
| series | Oncology Reviews |
| spelling | doaj.art-0b9201e0cdba4c36892bca9c726d1cb82023-01-03T10:59:53ZengFrontiers Media S.A.Oncology Reviews1970-55571970-55652019-07-0113210.4081/oncol.2019.416CDK4/6 inhibitors in advanced breast cancer, what is beyond?Amrallah A. Mohammed0Hanaa Rashied1Fifi Mostafa Elsayed2Medical Oncology Department, Faculty of Medicine, Zagazig University, Egypt; King Salman Armed Forces Hospital, Tabuk CityEl-mabra Hospital, ZagazigClinical Oncology & Nuclear Medicine, Department Faculty of Medicine Suez Canal UniversityResistant to hormonal treatment considered the main clinical challenge in the management of advanced breast cancer (ABC). The use of CDK4/6 inhibitors (CDK4/6I) may change the treatment landscape. In this mandated review, we will focus on the applicable role of CDK4/6I in the management of HR+/HER2- ABC, mechanisms of resistance, and promising future implementation.https://www.oncologyreviews.org/index.php/or/article/view/416Breast cancerCDK4/6 inhibitorspredictors of response and resistance. |
| spellingShingle | Amrallah A. Mohammed Hanaa Rashied Fifi Mostafa Elsayed CDK4/6 inhibitors in advanced breast cancer, what is beyond? Oncology Reviews Breast cancer CDK4/6 inhibitors predictors of response and resistance. |
| title | CDK4/6 inhibitors in advanced breast cancer, what is beyond? |
| title_full | CDK4/6 inhibitors in advanced breast cancer, what is beyond? |
| title_fullStr | CDK4/6 inhibitors in advanced breast cancer, what is beyond? |
| title_full_unstemmed | CDK4/6 inhibitors in advanced breast cancer, what is beyond? |
| title_short | CDK4/6 inhibitors in advanced breast cancer, what is beyond? |
| title_sort | cdk4 6 inhibitors in advanced breast cancer what is beyond |
| topic | Breast cancer CDK4/6 inhibitors predictors of response and resistance. |
| url | https://www.oncologyreviews.org/index.php/or/article/view/416 |
| work_keys_str_mv | AT amrallahamohammed cdk46inhibitorsinadvancedbreastcancerwhatisbeyond AT hanaarashied cdk46inhibitorsinadvancedbreastcancerwhatisbeyond AT fifimostafaelsayed cdk46inhibitorsinadvancedbreastcancerwhatisbeyond |